

### **REMARKS**

Claims 1-16 were previously canceled. Claim 17 has been amended, claims 22-25 have been canceled without prejudice, and new claim 27 has been added. Claims 17-21, 26 and 27 are now pending for the Examiner's consideration.

Applicants respectfully request reconsideration and withdrawal of the outstanding objections and rejections, in light of the foregoing amendments and following remarks.

The specification has been amended on page 1 to correct and update the priority claim. On pages 2 and 9, paragraphs have been amended to correct literature citations. The specification has further been amended in several places to insert SEQ ID NO. designations. No new matter is added.

By the present amendments, claim 17 has been amended to incorporate the limitation of claim 25, now canceled. New claim 27 has also been added to present claim 26 in independent form. No new matter is added.

For the reasons that follow, Applicants believe all claims are now in condition for allowance.

#### **Specification**

The Examiner indicates on page 2 of the Office Action that the specification is objected to because the application recites primer sequences without their SEQ ID number identifiers. Applicants herewith note that the specification has been amended, as listed above, in several places to insert the proper SEQ ID NO. designations.

#### **Rejection under 35 U.S.C. § 112**

Claims 17-26 were rejected under 35 U.S.C. § 112, first paragraph, for the reasons set forth on pages 3-8 of the Office Action. Claim 17 has been amended to clarify that the modified RTK polypeptides are VEGFR-2 polypeptide and modified VEGFR-2 polypeptide. Claims 18-20 and 26 have been previously presented. Claims 22-25 have been canceled without prejudice. Applicants believe that these claim amendments overcome the rejection under § 112, first paragraph, and respectfully request that the rejection be withdrawn.

#### **Claim Objections**

Claims 25 and 26 were objected to for being dependent on a rejected base claim. Claim 17 has been amended to include the recitations of claim 25, and should be in condition for allowance, along with claim 26, which depends there from. Claim 25 has been canceled. Applicants believe that these claim amendments overcome the claim objections and respectfully request that the objection be withdrawn.

**Conclusion**

Applicants believe all claims are now in condition for allowance. Should there be any issues that have not been addressed to the Examiners satisfaction, Applicants invite the Examiner to contact the undersigned attorney.

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time (for which Applicant hereby petitions), please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: July 13, 2004

Reena R. Desai  
Reena R. Desai  
Registration No. 53,833

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-3087  
Fax: (858) 678-8233